ASX:RAC OTC:RAONF

Race Oncology Ltd

Market:

ASX

Price

1.42 AUD

Day Change

2.16%

Market Cap:

$246.7 m

52 weeks high

2.09

52 weeks low

0.92

Filter by article type

Viewing results 1-25 of 155

News

Race Oncology bolsters clinical leadership with senior appointments to drive RC220 program

2 weeks, 6 days ago

Race Oncology progressing a robust pipeline of clinical activities for bisantrene

2 weeks, 6 days ago

Video

RC220 advances: Race Oncology hits key dosing milestone

3 weeks, 2 days ago

News

Race Oncology hails key milestone with first patient safely dosed in RC220 solid tumour clinical trial

3 weeks, 3 days ago

News

Race Oncology advances Phase 1 trial for RC220 and maintains strong cash position during March quarter

on 23/4/25

News

Race Oncology Phase 1 solid tumour clinical trial for RC220 opens at a second Australian site

on 22/4/25

Video

Race Oncology launches Phase I RC220 trial in Australia

on 4/4/25

News

Race Oncology opens first Australian site for RC220 Phase 1 solid tumour trial

on 3/4/25

News

ASX set for steady start as RBA expected to hold rates and markets eye US tariff moves

on 1/4/25

News

Race Oncology secures human ethics approval for Phase 1 RC220 trial in combination with doxorubicin

on 1/4/25

Safer chemotherapy? Race Oncology’s new drug heads to trials

on 28/3/25

News

Race Oncology initiates Australian site for Phase I solid tumour trial

on 28/3/25

Video

Daniel Tillett on Race Oncology's drug advancements

on 21/3/25

News

Race Oncology CEO on chemotherapy challenges and innovations in cancer treatment

on 19/3/25

Video

Race Oncology’s RC220 trial gets green light

on 18/3/25

News

Race Oncology garners ethics approval for RC220 Phase 1 solid tumour trial

on 14/3/25

Video

Daniel Tillett on Race Oncology’s drug advancements

on 7/3/25

News

Race Oncology partners with George Clinical for multi-site Phase 1 trial

on 5/3/25

News

Race Oncology makes significant quarterly progress in Phase 1 RC220 trial

on 31/1/25

Video

Oncology outlook: ASX small caps driving innovation in cancer treatment

on 24/1/25

Oncology market projected to soar in 2025 and beyond

on 23/1/25

News

Race Oncology adds visionary biotech executive to its board

on 18/12/24

News

Race Oncology secures A$5.25 million R&D tax rebate for FY2024

on 17/12/24

Video

Race Oncology on RC220 ethics, 2024 milestones and 2025 outlook

on 5/12/24

News

Race Oncology submits human ethics for RC220 Phase 1 solid tumour trial

on 5/12/24

	
		OSZAR »